Replies to post #76944 on Biotech Values

[masterlongevity]

all these new MS treatement options is great news for patients. Looks like a pretty seminal AAN from an MS perspective

[genisi]

Oral Cladribine's CLARITY trial

Both groups had fewer brain lesions than those in the placebo group and showed more than 30 percent reduction in the risk of disability progressing, compared with placebo, Merck said.

While the reduction in relapse rates were impressive, effect on progression of disability, which was the trial's secondary endpoint, was quite unimpressive.